These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18387935)

  • 21. [The endocannabinoid system and treatment of obesity].
    Aronsen L
    Tidsskr Nor Laegeforen; 2008 Feb; 128(5):570-1. PubMed ID: 18311201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Play an ADAGIO with a STRADIVARIUS: the right patient for CB1 receptor antagonists?
    Di Marzo V
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):610-2. PubMed ID: 18695695
    [No Abstract]   [Full Text] [Related]  

  • 23. Update on rimonabant--a selective cannabinoid CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2006 May; 40(5):994. PubMed ID: 16638915
    [No Abstract]   [Full Text] [Related]  

  • 24. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
    Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
    J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CB1 cannabinoid receptor inhibition: promising approach for heart failure?
    Mukhopadhyay P; Mohanraj R; Bátkai S; Pacher P
    Congest Heart Fail; 2008; 14(6):330-4. PubMed ID: 19076859
    [No Abstract]   [Full Text] [Related]  

  • 26. Cannabinoid receptor CB1 antagonists state of the art and challenges.
    Bifulco M; Santoro A; Laezza C; Malfitano AM
    Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cardiac metabolic risk factors. CB1-blocker corrects three with one stroke].
    MMW Fortschr Med; 2006 Aug; 148(35-36):48. PubMed ID: 16995368
    [No Abstract]   [Full Text] [Related]  

  • 28. [Rimonabant (Acomplia)].
    Duh D; Vanddevijver A
    J Pharm Belg; 2008 Mar; 63(1):27-8. PubMed ID: 18479080
    [No Abstract]   [Full Text] [Related]  

  • 29. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks.
    Gadde KM; Allison DB
    Circulation; 2006 Aug; 114(9):974-84. PubMed ID: 16940206
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
    Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
    J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of rimonabant on weight and cardiometabolic risk factors.
    Gadde KM
    JAMA; 2006 Aug; 296(6):649-50; author reply 650-1. PubMed ID: 16896103
    [No Abstract]   [Full Text] [Related]  

  • 32. Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
    Immenschuh S
    Cardiovasc Res; 2009 Dec; 84(3):341-2. PubMed ID: 19819883
    [No Abstract]   [Full Text] [Related]  

  • 33. Rehabilitating rimonabant.
    Luft FC
    J Mol Med (Berl); 2013 Jul; 91(7):777-9. PubMed ID: 23591956
    [No Abstract]   [Full Text] [Related]  

  • 34. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.
    Warren KR; Buchanan RW; Feldman S; Conley RR; Linthicum J; Ball MP; Liu F; McMahon RP; Gorelick DA; Huestis MA; Kelly DL
    J Clin Psychopharmacol; 2013 Feb; 33(1):118-20. PubMed ID: 23277241
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiometabolic risk modification: current trends and emerging therapies.
    Lillo JL; Bray G; Woods SC; Henry RR; Hadley RD
    JAAPA; 2006 Dec; Suppl Cardiometabolic():3-14; quiz 15-6. PubMed ID: 17354517
    [No Abstract]   [Full Text] [Related]  

  • 36. The endocannabinoid system as a novel approach for managing obesity.
    Lillo JL
    J Am Osteopath Assoc; 2007 Apr; 107(4 Suppl 2):S12-20. PubMed ID: 17784530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple impacts of rimonabant on cardiometabolic risk and safety addressed at ESC congress, Vienna.
    Cardiovasc J Afr; 2007; 18(5):336-7. PubMed ID: 17985035
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
    Després JP; Golay A; Sjöström L;
    N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rimonabant--a selective CB1 antagonist.
    Boyd ST; Fremming BA
    Ann Pharmacother; 2005 Apr; 39(4):684-90. PubMed ID: 15755787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
    Bifulco M; Pisanti S
    Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.